| Recruiting | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response NCT07284667 | ACADIA Pharmaceuticals Inc. | Phase 2 |
| Recruiting | A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression NCT07053345 | Janssen Korea, Ltd., Korea | Phase 4 |
| Recruiting | Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression NCT06854367 | Centre for Addiction and Mental Health | N/A |
| Recruiting | Intravenous Ketamine for Treatment-Resistant Depression NCT06668571 | Mayo Clinic | Phase 2 |
| Completed | Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression NCT06650800 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Recruiting | Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Trea NCT06511908 | National Institute of Mental Health (NIMH) | Phase 2 |
| Terminated | Behavioural Activation Therapy and Esketamine for Resistant Depression NCT06431386 | The Royal's Institute of Mental Health Research | N/A |
| Unknown | Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression NCT06323486 | Ontario Shores Centre for Mental Health Sciences | N/A |
| Unknown | Chronic Anergic-anhedonic Depression Open Trial NCT06110507 | University Hospital, Strasbourg, France | — |
| Completed | Psilocybin-assisted Interpersonal Therapy for Depression NCT05581797 | University of Otago | N/A |
| Recruiting | rTMS With and Without Text4Support for the Treatment of Resistant Depression. NCT05570344 | University of Alberta | N/A |
| Unknown | In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells NCT05887310 | University of Milano Bicocca | — |
| Recruiting | OSU6162 as add-on in SSRI/SNRI-resistant Depression NCT05641623 | Göteborg University | Phase 2 |
| Completed | Synaptic Imaging and Network Activity in Treatment Resistant Depression NCT05870501 | King's College London | N/A |
| Completed | Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine NCT04977674 | King's College London | EARLY_Phase 1 |
| Recruiting | Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment NCT04956016 | Centre Hospitalier Henri Laborit | N/A |
| Unknown | Sevoflurane for Treatment-Resistant Depression NCT05008939 | Shanghai First Maternity and Infant Hospital | N/A |
| Unknown | Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation NCT05390593 | Chang Gung Memorial Hospital | N/A |
| Recruiting | Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study NCT04783103 | Universitair Ziekenhuis Brussel | N/A |
| Unknown | IMPase in Treatment-resistant Depression NCT05117710 | University of Oxford | Phase 1 |
| Active Not Recruiting | Dopaminergic Dysfunction in Late-Life Depression NCT04469959 | Vanderbilt University Medical Center | Phase 2 |
| Completed | Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression NCT04701866 | Douglas Mental Health University Institute | N/A |
| Completed | A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant NCT04599855 | Janssen Research & Development, LLC | Phase 4 |
| Completed | rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) NCT04239651 | University of Alberta | N/A |
| Withdrawn | NESBID: Neuro-Stimulation of the Brain in Depression NCT04159012 | University of Alberta | N/A |
| Unknown | Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression NCT04428099 | University of the Balearic Islands | N/A |
| Withdrawn | A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus NCT03852160 | Janssen-Cilag International NV | Phase 3 |
| Active Not Recruiting | Improving Brain Stimulation Through Imaging NCT03851380 | VA Office of Research and Development | — |
| Completed | Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal NCT04216888 | Dan Iosifescu | Phase 2 / Phase 3 |
| Completed | Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. NCT03887624 | Zhejiang University | EARLY_Phase 1 |
| Completed | Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depre NCT03756129 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Biomarkers of Theta Burst Stimulation in Major Depressive Disorder NCT03626181 | University of Calgary | N/A |
| Completed | A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Es NCT03434041 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 NCT03051256 | Relmada Therapeutics, Inc. | Phase 2 |
| Completed | Treatment-Resistant Depression Cohort in Europe NCT03373253 | Janssen-Cilag Ltd. | — |
| Completed | Treatment Resistant Depression in America Latina NCT03207282 | Janssen-Cilag, S.A. | — |
| Terminated | Adaptive tDCS for Treatment-Resistant MDD NCT02942368 | Washington University School of Medicine | Phase 1 |
| Terminated | NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits NCT02994433 | Washington University School of Medicine | Phase 1 |
| Completed | An Epidemiology Study of Treatment Resistant Depression in the United States (US) NCT03109002 | Janssen Research & Development, LLC | — |
| Completed | Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies NCT03283670 | Washington University School of Medicine | Phase 2 |
| Unknown | Lithium Versus Quetiapine in Treatment Resistant Depression NCT03004521 | King's College London | Phase 4 |
| Completed | A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression NCT02782104 | Janssen Research & Development, LLC | Phase 3 |
| Terminated | Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression NCT03360942 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With NCT02493868 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Epidemiology of Treatment Resistant Depression in Taiwan NCT02691520 | Janssen Research & Development, LLC | — |
| Completed | Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) NCT02452892 | Tal Medical, Inc. | N/A |
| Completed | A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressan NCT02422186 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Ketamine Infusions for PTSD and Treatment-Resistant Depression NCT02577250 | Minneapolis Veterans Affairs Medical Center | Phase 1 |
| Completed | Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial NCT02263872 | Pakistan Institute of Living and Learning | Phase 4 |
| Completed | Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive NCT02153502 | Avanir Pharmaceuticals | Phase 2 |
| Unknown | Clinical Trial of the Use of Ketamine in Treatment Resistant Depression NCT02610712 | National Institute of Neurology and Neurosurgery, Mexico | Phase 4 |
| Completed | DBS for Treatment Resistant Depression NCT01983904 | University of Calgary | N/A |
| Completed | Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) NCT01898429 | Paul Holtzheimer | N/A |
| Completed | Treatment Resistant Depression (Pilot) NCT01179009 | Washington University School of Medicine | N/A |
| Approved For Marketing | Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD) NCT03829579 | Janssen Research & Development, LLC | — |